Poster presentation highlights NL-201 activity in multiple myeloma stem cell transplant model Abstract reports activity of NL-201 as monotherapy and anti-PD1 combination in non-Hodgkin lymphoma model SEATTLE, Dec. 11, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., Neoleukin (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the presentation of preclinical data on NL-201 in multiple myeloma at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition taking place virtually and in person December 11-14, 2021. Additionally, a published abstract in Blood reports on NL-201 antitumor activity in preclinical studies of non-Hodgkin lymphoma
Recent Comments